Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
Molecular Cancer Therapeutics|May 15, 2020
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast CancerSandra Zazo, Paula González-Alonso, Ester Martín-Aparicio, et al.
Neoplasia (New York, N.Y.)|July 18, 2014
Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanomaAsunción Fernández-Barral, Jose Luis Orgaz, Pablo Baquero, et al.
The Oncologist|June 26, 2019
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)Xabier García-Albéniz, Vicente Alonso, Pilar Escudero, et al.
Molecular Cancer Research : MCR|March 29, 2022
mTOR Inhibition and T-DM1 in HER2-Positive Breast CancerDavid Casadevall, Anna Hernández-Prat, Sara García-Alonso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 26, 2011
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinomaCarlos Gómez-Martín, Angel Concha, José María Corominas, et al.
Physiological Genomics|September 23, 2024
Exercise and tumor proteome: insights from a neuroblastoma modelAbel Plaza-Florido, Beatriz G Gálvez, Juan A López, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA StudyMartin Filipits, Urania Dafni, Michael Gnant, et al.
Neoplasia (New York, N.Y.)|May 30, 2018
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer PatientsVicente Alonso, Pilar Escudero, Carlos Fernández-Martos, et al.
Theranostics|November 22, 2017
DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through <i>MAFG</i> Overexpression in Cancer CellsOlga Vera, Julia Jimenez, Olga Pernia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumorsJosep Tabernero, Federico Rojo, Emiliano Calvo, et al.
Pageof 23